Clinical trial · Observational
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
NCT02136836CI-TRIAL-00014499HER2unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- gastric adenocarcinoma
Primary outcomes (1)
- measure
- The proportion of HER2 overexpression in gastric cancer patients
- timeFrame
- 8 years
Secondary outcomes (1)
- measure
- Gastric cancer specific survival according to HER2 expression in each stage
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma 2. Patients were diagnosed during 2006-2013 3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion. Exclusion Criteria: * Patients with second primary cancer within 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.